BRCA1 Immunohistochemical Staining as a Prognostic Indicator in Uterine Serous Carcinoma

被引:6
作者
Beirne, James P.
Quinn, Jennifer E. [1 ]
Maxwell, Perry [1 ]
Kalloger, Steve E. [2 ]
McAlpine, Jessica [3 ,4 ]
Gilks, C. Blake [2 ]
Harley, Ian J. G. [5 ]
McCluggage, W. Glenn [1 ,6 ]
机构
[1] Queens Univ Belfast, Mol Pathol Programme, Ctr Canc Res & Cell Biol, Belfast BT7 1NN, Antrim, North Ireland
[2] Vancouver Gen Hosp, Dept Pathol & Lab Med, Vancouver, BC, Canada
[3] Vancouver Gen Hosp, Dept Obstet & Gynaecol, Vancouver, BC, Canada
[4] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[5] Belfast Hlth & Social Care Trust, Dept Gynaecol Oncol, Belfast, Antrim, North Ireland
[6] Belfast Hlth & Social Care Trust, Dept Pathol, Belfast, Antrim, North Ireland
关键词
BRCA1; Immunohistochemistry; Uterine serous carcinoma; Prognosis; EPITHELIAL OVARIAN-CANCER; GERM-LINE MUTATIONS; ENDOMETRIAL CANCER; BREAST-CANCER; PAPILLARY CARCINOMA; SPORADIC OVARIAN; JEWISH PATIENTS; WOMEN; CHEMOTHERAPY; SURVIVAL;
D O I
10.1097/IGC.0b013e3182798188
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: The objective of this study was to investigate the relationship between BRCA1 protein expression, as determined by immunohistochemistry, and clinical outcome in uterine serous carcinoma (USC). Methods: A tissue microarray containing duplicate cores of 73 cases of USC was immunohistochemically stained with mouse anti-BRCA1 (Ab-1) mouse monoclonal (MS 110) antibody. The cores were scored in a semiquantitative manner evaluating both the distribution and intensity of nuclear staining. BRCA1 protein expression was correlated with progression-free survival. Results: Seventy-two of 73 cases were assessable, and there was a statistically significant decreased progression-free survival for those cases exhibiting tumor cell nuclei staining of 76% or greater (P = 0.0023). Conclusions: Our study illustrates that a low level of BRCA1 protein expression is a favorable prognostic indicator in USC, similar to what is observed in high-grade serous ovarian carcinoma. Further studies should focus on the BRCA1 status of USCs at a molecular level and also investigate whether BRCA1 protein expression is associated with response to chemotherapy in USC.
引用
收藏
页码:113 / 118
页数:6
相关论文
共 28 条
  • [1] Aida H, 1998, CLIN CANCER RES, V4, P235
  • [2] High-Grade Endometrial Carcinoma: Serous and Grade 3 Endometrioid Carcinomas Have Different Immunophenotypes and Outcomes
    Alkushi, Abdulmohsen
    Koebel, Martin
    Kalloger, Steve E.
    Gilks, C. Blake
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2010, 29 (04) : 343 - 350
  • [3] The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations.: A prospective study
    Beiner, Mario E.
    Finch, Amy
    Rosen, Barry
    Lubinski, Jan
    Moller, Pal
    Ghadirian, Parviz
    Lynch, Henry T.
    Friedman, Eitan
    Sun, Ping
    Narod, Steven A.
    [J]. GYNECOLOGIC ONCOLOGY, 2007, 104 (01) : 7 - 10
  • [4] High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma
    Biron-Shental, T.
    Drucker, L.
    Altaras, M.
    Bernheim, J.
    Fishman, A.
    [J]. EJSO, 2006, 32 (10): : 1097 - 1100
  • [5] Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
    Bolton, Kelly L.
    Chenevix-Trench, Georgia
    Goh, Cindy
    Sadetzki, Siegal
    Ramus, Susan J.
    Karlan, Beth Y.
    Lambrechts, Diether
    Despierre, Evelyn
    Barrowdale, Daniel
    McGuffog, Lesley
    Healey, Sue
    Easton, Douglas F.
    Sinilnikova, Olga
    Benitez, Javier
    Garcia, Maria J.
    Neuhausen, Susan
    Gail, Mitchell H.
    Hartge, Patricia
    Peock, Susan
    Frost, Debra
    Evans, Gareth
    Eeles, Rosalind
    Godwin, Andrew K.
    Daly, Mary B.
    Kwong, Ava
    Ma, Edmond S. K.
    Lazaro, Conxi
    Blanco, Ignacio
    Montagna, Marco
    D'Andrea, Emma
    Nicoletto, Maria Ornella
    Johnatty, Sharon E.
    Krueger, Susanne
    Jensen, Allan
    Hogdall, Estrid
    Goode, Ellen L.
    Fridley, Brooke L.
    Loud, Jennifer T.
    Greene, Mark H.
    Mai, Phuong L.
    Chetrit, Angela
    Lubin, Flora
    Hirsh-Yechezkel, Galit
    Glendon, Gord
    Andrulis, Irene L.
    Toland, Amanda E.
    Senter, Leigha
    Gore, Martin E.
    Gourley, Charlie
    Michie, Caroline O.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (04): : 382 - 390
  • [6] Clinicopathologic features of BRCA-linked and sporadic ovarian cancer
    Boyd, J
    Sonoda, Y
    Federici, MG
    Bogomolniy, F
    Rhei, E
    Maresco, DL
    Saigo, PE
    Almadrones, LA
    Barakat, RR
    Brown, CL
    Chi, DS
    Curtin, JP
    Poynor, EA
    Hoskins, WJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (17): : 2260 - 2265
  • [7] BRCA1/2 Germline Mutations in Jewish Patients With Uterine Serous Carcinoma
    Bruchim, Ilan
    Amichay, Keren
    Kidron, Dvora
    Attias, Zohar
    Biron-Shental, Tal
    Drucker, Liat
    Friedman, Eitan
    Werner, Haim
    Fishman, Ami
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (07) : 1148 - 1153
  • [8] BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer
    Carser, Judith E.
    Quinn, Jennifer E.
    Michie, Caroline O.
    O'Brien, Eamonn J.
    McCluggage, W. Glenn
    Maxwell, Perry
    Lamers, Elisabeth
    Lioe, Tong F.
    Williams, Alistair R. W.
    Kennedy, Richard D.
    Gourley, Charlie
    Harkin, D. Paul
    [J]. GYNECOLOGIC ONCOLOGY, 2011, 123 (03) : 492 - 498
  • [9] Geisler JP, 2002, JNCI-J NATL CANCER I, V94, P61
  • [10] Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?
    Goshen, R
    Chu, W
    Elit, L
    Pal, T
    Hakimi, J
    Ackerman, I
    Fyles, A
    Mitchell, M
    Narod, SA
    [J]. GYNECOLOGIC ONCOLOGY, 2000, 79 (03) : 477 - 481